

# Resource Summary Report

Generated by SPARC SAWG on Sep 19, 2026

## HALT-C Trial

RRID:SCR\_001534

Type: Tool

---

### Proper Citation

HALT-C Trial (RRID:SCR\_001534)

---

### Resource Information

**URL:** <https://repository.niddk.nih.gov/study/81>

**Proper Citation:** HALT-C Trial (RRID:SCR\_001534)

**Description:** Multi-center, randomized controlled study designed to determine if continuing interferon long term over several years will suppress the Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation. Patient enrollment began in 2000 and was completed in 2003 at 10 clinical centers, which were supported by a data coordinating center, virological testing center, and central sample repository. Patients with chronic hepatitis C and advanced fibrosis or cirrhosis on liver biopsy who failed to respond to a previous course of interferon alfa were enrolled in this study. Patients were initially treated with a 24-week course of peginterferon alfa-2a and ribavirin. Patients who remained hepatitis C virus RNA positive were then randomized to receive maintenance, low-dose peginterferon or to be followed on no treatment. Liver biopsies were done before enrollment and after 2 and 4 years of treatment or follow-up. The endpoints were development of cirrhosis, hepatic decompensation, hepatocellular carcinoma, death, or liver transplantation. 1050 patients were randomized and followed through the 4 year randomized phase of the trial and as long as 4 years off treatment. Serum samples collected at multiple time points, DNA and liver tissue are available for scientific investigation.

**Abbreviations:** HALT-C Trial, HALT-C

**Synonyms:** Hepatitis C Antiviral Long-term Treatment against Cirrhosis, Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial, Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial

**Resource Type:** bibliography, clinical trial, data or information resource, resource

**Keywords:** interferon, progression, cirrhosis, prevention, liver cancer, liver transplantation, liver, pegylated interferon, clinical, outcome, adult human, dna, liver tissue, serum, blood, b lymphoblastoid cell-line, epstein-barr virus infection in peripheral blood mononuclear cell, peripheral blood mononuclear cell, biomaterial supply resource,

formalin fixed, histology, frozen, stained liver slide, unstained liver slide, advanced fibrosis, liver biopsy, peginterferon alfa-2a, ribavirin

**Related Condition:** Hepatitis C virus, Chronic hepatitis C

**Funding:** NIDDK

**Availability:** Free, Freely available

**Resource Name:** HALT-C Trial

**Resource ID:** SCR\_001534

**Alternate IDs:** nlx\_152835

**Alternate URLs:**

<http://archives.niddk.nih.gov/haltctrial/displaypage.aspx?pagename=haltctrial/index.htm>

**Old URLs:** <http://www.haltctrial.org/>

**Record Creation Time:** 20220129T080208+0000

**Record Last Update:** 20260912T195527+0000

---

## Ratings and Alerts

No rating or validation information has been found for HALT-C Trial .

No alerts have been found for HALT-C Trial .

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We have not found any literature mentions for this resource.